Published in Hepatitis Weekly, May 4th, 2009
The combination of Hadasitís oral immune modulation with Immuronís existing oral protein and antibody technology could yield a convenient, all-natural, side-effect-free approach to address serious diseases which have multi-billion dollars markets, including metabolic syndrome, hepatitis C and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly